BioSante and Antex vaccine collaboration

BTPH signed an option license agreement with ATXB to develop BTPH's calcium phosphate nanoparticle (CAP) technology as a vaccine adjuvant. ATXB will evaluate in animal models vaccines against Chlamydi...